Kinstrie et al. identified a novel population of primitive Lin−CD34+CD38−CD90+ LSCs expressing the transmembrane receptor CD93 which persisted in CML patients despite extended TKI treatment [65••]. This evidence concerns the gene CD93 and chronic myelogenous leukemia, BCR-ABL1 positive.